The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of camrelizumab (SHR-1210) plus apatinib with or without stereotactic body radiotherapy (SBRT) as higher-line therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC).
 
Rui Meng
No Relationships to Disclose
 
Lu Wu
No Relationships to Disclose
 
Kai Zhang
No Relationships to Disclose
 
KuiKui Zhu
No Relationships to Disclose
 
Gang Wu
No Relationships to Disclose
 
Li Liu
No Relationships to Disclose